AstraZeneca AB v Alphapharm Pty Ltd

In the case of AstraZeneca AB v Alphapharm Pty Ltd, the applicant, AstraZeneca AB, sought an injunction against the respondent, Alphapharm Pty Ltd, for alleged patent infringement relating to pharmaceutical products. The Federal Court of Australia was tasked with determining the scope and validity of the patents in question and the appropriate remedies and costs to be awarded. The court was also required to decide whether the applicant was entitled to solicitor/client costs under section 19(2) of the Patents Act 1990 (Cth), and if the court had discretion to depart from this presumption under section 19(3) of the same Act.

The court found that the applicant was entitled to the relief sought, including permanent injunctions against the respondent's infringement of the patents and restrictions on the respondent's ability to assign the Australian Register of Therapeutic Goods registrations of the products in question. The court held that the respondent had failed to present a complete offer to settle the case, and that the applicant had not engaged in unduly aggressive litigation. Consequently, the court determined that the discretion provided by section 19(3) of the Patents Act should not be exercised, and the applicant was entitled to costs on a solicitor/client basis as per section 19(2).

The final orders included comprehensive injunctions against the respondent's infringement activities, a release of the applicant from a prior undertaking to compensate any adversely affected parties, and a direction that the respondent pay the applicant's costs of the proceeding in accordance with section 19(2) of the Patents Act. The costs were to be taxed, if necessary, in conformity with the statutory provisions.